Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumour-specific targets derived from the dark proteome.

Entelo Bio selected as one of 20 global teams to pioneer AI target discovery in ALS

Entelo Bio has been named one of 20 global winners of the Longitude Prize on ALS, receiving funding and access to one of the world’s largest ALS datasets to support AI-driven drug target discovery. In this interview, the Oxford spinout shares how the award will accelerate its platform development, collaborative research, and expansion into neuromuscular disease.

Entelo Bio raises $4M to transform human physical resilience

Entelo Bio, an AIxBio company focused on the biology of movement and ageing, emerges from stealth today with a total of $4 million in funding, led by Ananda Impact Ventures, with participation from The Creator Fund and US and European bio- and tech-focused angels.

Enara Bio presents first-in-class DARKFOX-Targeting bispecific T Cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential in solid tumour immunotherapy

ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumour-specific targets derived from the dark proteome.

Alethio Therapeutics unveils ATX‑011, a breakthrough, mutation‑agnostic antibody for treating essential thrombocythemia – a c.$2B market, and strengthens leadership to accelerate path to IND

Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. Alongside this, the Company announces the appointment of Steve R. Coats, PhD, a veteran biologics leader, as Chief Development Officer, to advance the ATX-011 programme towards IND submission, targeted for Q1 2027.

Bioarchitech secures strategic material license with the UK Health Security Agency (UKHSA) to support manufacturing and clinical development of BA-V151

Bioarchitech, Oxford, UK, an immuno-oncology therapeutics start-up company announces that it has secured a material license from the European Collection of Authenticated Cell Cultures (ECACC), UKHSA for a mammalian cell line to be developed as a scalable and high yield viral manufacturing platform and for the vector backbone of BA-V151, a preclinical stage candidate being developed as a treatment for metastatic cancers.

PepGen announces topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing phase 2 FREEDOM2 study demonstrating favourable safety, splicing and vHOT data

PGN-EDODM1 was generally well-tolerated, with all adverse events being mild or moderate, and no serious adverse events reported. The mean splicing correction observed with PGN-EDODM1 (n=6) was 7.3%, compared to 6.8% for the placebo (n=2). Excluding one outlier patient, the treatment group showed a mean splicing correction of 22.9% (n=5). Promising trends were seen in vHOT in the PGN-EDODM1 treated group. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027.

BioEscalator joins Equinox partnership to drive inclusive growth

The BioEscalator is proud to be a founding signatory of Equinox (Equitable Innovation Oxford), a new initiative connecting research, business and communities to accelerate innovation and deliver inclusive growth in Oxford and the wider region.

Cardiovascular clinical scientist & diagnostic entrepreneur Professor Paul Leeson joins the BioEscalator Management Board

We are delighted to welcome Professor Paul Leeson to our Management Board - an expert in cardiovascular imaging and preventive cardiology, entrepreneur and supporter of translational research and spin-out creation.

Enara Bio to unveil first-in-class DARKFOX-targeting bispecific T cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential for solid tumour immunotherapy

Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX®, a novel cancer-specific Dark Antigen discovered with Enara’s EDAPT® platform.

BioEscalator Bulletin - Spring 2026

Stay informed with the latest BioEscalator updates, tenant and alumni news in the Spring 2026 edition of the BioEscalator Bulletin.

OSE announces new board appointments

Professor Dame Molly Stevens joins as a Non-Executive Director and University representative. Professor Richard Hobbs also joins as a Non-Executive Director. Simon Boddie, the Chief Financial Officer of the University of Oxford, steps down.

International Women’s Day 2026: Celebrating Success Across the Bioscience Ecosystem

Q: What kind of biosciences event features being an actress, being a cool kid, twin babies, presenting to empty lecture theatres, offices with no toilets for women, and mentorship schemes that don’t work? A: The BioEscalator’s celebration of International Women’s Day 2026.

Let’s just get married – the story of an acquisition

"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.

Theolytics awarded €8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer

Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.

Infinitopes: Preventing Cancer Recurrence

Infinitopes has been featured in a recent blog post by VC Amplify Partners, highlighting its work to prevent cancer recurrence and its approach to advancing precision cancer vaccines.

U-Ploid Biotechnologies launches collaborative research study with San Diego Fertility Center and Nova Genomics

U-Ploid Biotechnologies has initiated a new collaborative research study with San Diego Fertility Center (SDFC) and Nova Genomics, marking an important translational step in the company’s programme to address the biological causes of age-related infertility.

BiotechTV talks to clinical-stage tenant Infinitopes on its second BioEscalator visit

On its recent visit to Oxford, leading biotech sector commentator Biotech TV had a fascinating and wide-ranging conversation with Dr Jonathan Kwok, the CEO of BioEscalator tenant Infinitopes.

CyanoCapture and Persist AI announce strategic collaboration to build world's first robotic GMP facility for oral protein and peptide drugs

The pioneering partnership combines cyanobacteria-based oral delivery with AI-driven robotics to transform how life-saving biologics reach patients.

Highlighting our award-winning apprentices in NAW 2026

Apprentices are a vital part of BioEscalator life, and we always enjoy celebrating their achievements and impact in National Apprenticeship Week.

Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer

Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment reflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.

Load More

Similar stories